Aktie A3DFJ8 MOUNTAIN CREST ACQUISITION CORP. V
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Mountain Crest Acquisition Corp. V

Aktien

A3DFJ8

US62404B1070

MCAG

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:30:00 02.05.2024 		% 5 Tage % 1. Jan.
10,6 USD +1,24 % Intraday Chart für Mountain Crest Acquisition Corp. V -1,40 % -0,66 %
2023 Mountain Crest Acquisition Corp. V meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 30. September 2023 CI
2023 Mountain Crest Acquisition Corp. V meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 30. Juni 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
CUBEBIO Co., Ltd. entered into terms relating to a potential business combination with Mountain Crest Acquisition Corp. V
Mountain Crest Acquisition : New Financial Obligation - Form 8-K
Mountain Crest Acquisition Corp. V announced that it has received $0.3 million in funding
Mountain Crest Acquisition Corp. V Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Mountain Crest Acquisition Corp. V announced that it has received $0.4 million in funding
Mountain Crest Acquisition Corp. V Primary Exchange Listing will Change to Nasdaq Capital Market from Nasdaq Global Market
Mountain Crest Acquisition Corp. V Announces Listing Transfer to the Nasdaq Capital Market
Mountain Crest Acquisition Corp. V Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Mountain Crest Acquisition : Termination of Material Agreement - Form 8-K
MOUNTAIN CREST ACQUISITION CORP. V : Termination of a Material Definitive Agreement (form 8-K)
AUM Biosciences Pte. Ltd. cancelled the acquisition of Mountain Crest Acquisition Corp. V from a group of shareholders in a reverse merger transaction.
AUM Biosciences Doses First Patient in Phase 2 Clinical Trial of AUM001 in Metastatic Colorectal Cancer
Mountain Crest Acquisition : Failure to Satisfy Listing Rule - Form 8-K
MOUNTAIN CREST ACQUISITION CORP. V : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
Mountain Crest Acquisition Corp. V Reports Earnings Results for the First Quarter Ended March 31, 2023
MOUNTAIN CREST ACQUISITION CORP. V : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AUM Biosciences to Participate in Inaugural EF Hutton Global Conference
MOUNTAIN CREST ACQUISITION CORP. V : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
MOUNTAIN CREST ACQUISITION CORP. V : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
MOUNTAIN CREST ACQUISITION CORP. V MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3DFJ8 Aktie
  4. Nachrichten Mountain Crest Acquisition Corp. V
  5. Andere Sprachen